Comparison of Ultrasound and Breast MRI for Breast Cancer Detection
Launched by SAMSUNG MEDICAL CENTER · Apr 2, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well two different imaging techniques—breast ultrasound and MRI—detect breast cancer in women who have a history of the disease. The researchers want to see which method provides better results for monitoring women after their initial treatment. The trial is currently looking for women between the ages of 20 and 75 who have had breast cancer but no signs of recurrence. To qualify, participants should have dense breast tissue and have not undergone any breast imaging tests in the past six months.
If you join this trial, you will receive regular check-ups that include annual mammograms, breast ultrasounds, and breast MRIs. The study aims to help improve breast cancer detection methods, which could benefit many women in the future. It’s important to know that certain conditions, like having current symptoms of breast cancer or a severe fear of enclosed spaces (claustrophobia), may prevent someone from participating. If you meet the criteria and are interested, this could be a significant opportunity to contribute to breast cancer research.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged 20-75 with a history of breast cancer (in situ carcinoma or invasive breast cancer \[stage 0-3\])
- • Women with dense breasts with pattern C (heterogeneously dense) or D (extremely dense breasts) using AI-based Lunit INSIGHT for Mammography (version 1.1.4.3, Lunit Inc.) in the most recent mammography
- • Women who have not had a breast imaging test within 6 months
- • Women who agreed to undergo regular annual mammography, breast ultrasound, and breast MRI
- Exclusion Criteria:
- • Patients with symptoms related to current breast cancer or breast cancer recurrence (palpable mass, bloody or transparent nipple secretion, palpable mass in the axillary region, abnormal skin changes in the breast or nipple)
- • If you have been diagnosed with regional recurrence (axillary lymph nodes, supraclavicular and subclavian lymph nodes, internal mammary lymph nodes, etc.) or distant metastases
- • In case of bilateral total mastectomy
- • If women are receiving chemotherapy for cancer in other organs
- • Women during pregnancy or lactation
- • Glomerular filtration rate \< 30 mL/min/1.73m2, or patients with renal insufficiency on dialysis
- • If women have severe claustrophobia
- • If women have a metal prosthesis that is not suitable for MR (e.g. breast tissue expander, etc.)
- • If there is a history of severe contrast agent side effects (e.g., anaphylactoid reaction, dyspnea, etc.)
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Busan, Busanjin Gu, Korea, Republic Of
Seoul, Gangnam Gu, Korea, Republic Of
Seoul, Yangchun Gu, Korea, Republic Of
Seoul, Yongsan Gu, Korea, Republic Of
Patients applied
Trial Officials
Eun Sook Ko, M.D., Ph.D.
Study Chair
Samsung Medical Center
Yung Mi Park, M.D., Ph.D.
Principal Investigator
Inje University
Yun woo Jang, M.D., Ph.D.
Principal Investigator
Soon Chun Hyang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials